Moderna (MRNA) Total Liabilities (2017 - 2026)

Moderna (MRNA) has reported Total Liabilities for 10 consecutive years, with $4.2 billion the latest figure, recorded in Q2 2026.

• On a quarterly basis, Total Liabilities rose 60.86% year-over-year to $4.2 billion in Q2 2026; TTM through Jun 2026 was $4.2 billion, a 60.86% increase from a year earlier, with the FY2025 full-year figure at $3.7 billion, up 13.79% from the prior year.
• Total Liabilities was $4.2 billion for Q2 2026 at Moderna, up from $4.1 billion in the prior quarter.
• Over five years, Total Liabilities peaked at $10.5 billion in Q1 2022 and troughed at $2.6 billion in Q2 2025.
• A 5-year average of $5.0 billion and a median of $4.1 billion in 2026 frame the typical range for Total Liabilities.
• Across the five-year window, Total Liabilities tumbled 50.05% in 2023 and surged 60.86% in 2026, its largest moves.
• Over 5 years, Total Liabilities stood at $6.7 billion in 2022, then plunged by 32.12% to $4.6 billion in 2023, then dropped by 29.11% to $3.2 billion in 2024, then advanced by 13.79% to $3.7 billion in 2025, then increased by 13.88% to $4.2 billion in 2026.
• The last three Total Liabilities figures came in at $4.2 billion (Q2 2026), $4.1 billion (Q1 2026), and $3.7 billion (Q4 2025), per Business Quant data.